

C-RAD SHOWCASES NEW DEVELOPMENTS AT ASTRO 2025

At ASTRO 2025 in San Francisco, C-RAD will showcase ongoing developments reflecting our continued focus on empowering clinicians with tools that make a meaningful impact in everyday cancer care. C-RAD's latest developments emphasize intuitive user experience and streamlined workflows, supporting healthcare professionals in delivering precise, efficient, and patient-centric treatment.

As part of our commitment to broadening access to advanced care, C-RAD will highlight Catalyst⁺ LITE* which is an accessible and scalable way for clinics to begin their Surface Guided Radiation Therapy (SGRT) Journey. Catalyst⁺ Lite enables high-precision motion management and secure, tattoo-less patient setup. Its modular design allows clinics to start with a robust entry-level system and seamlessly upgrade to Catalyst⁺ HD, ensuring long-term sustainability and value without the need for replacement.

C-RAD will also show ongoing developments* such as an updated user interface designed for clarity and usability as well as a new ergonomic workflow feature. The ergonomic workflow allows for a smoother, more intuitive setup experience with initial coarse posture correction to ensure optimal alignment as well as improved accessibility, while prioritizing clinician comfort.

In response to the growing adoption of ring gantry linear accelerators, C-RAD will also be demonstrating how the Catalyst enables full six degrees of freedom (6DoF) patient alignment prior to gantry entry. Unlike CBCT-based alignment, which is limited by couch mechanics, this approach ensures comprehensive positioning accuracy from the outset. By reducing the need for repeated imaging and corrections, clinics can streamline their workflow and save valuable time in the treatment room.

"At C-RAD, our mission is to support clinicians in delivering safe, efficient, and patient-centric care," said Cecilia de Leeuw, CEO and President of C-RAD. "Every development we bring forward is guided by the voices of clinicians and shaped by the real needs of patients."

These ongoing developments strengthen C-RAD's SGRT offering and underscore our ongoing collaboration with the clinical community to meet real-world needs.

C-RAD welcomes all ASTRO 2025 attendees to visit Booth 2225 to explore the latest product updates.

**) Not commercially available for sale in all markets, which also applies to the United States.*

For further information:

Cecilia de Leeuw, CEO, +46 (0)79 585 6677, investors@c-rad.com

Linda Frölén, CFO, +46 (0)70 303 3253, investors@c-rad.com

About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit <http://www.c-rad.com>

Attachments

C-RAD showcases new developments at ASTRO 2025